193 related articles for article (PubMed ID: 26421390)
21. PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype.
Ning YP; Kanai K; Tomiyama H; Li Y; Funayama M; Yoshino H; Sato S; Asahina M; Kuwabara S; Takeda A; Hattori T; Mizuno Y; Hattori N
Neurology; 2008 Apr; 70(16 Pt 2):1491-3. PubMed ID: 18413573
[No Abstract] [Full Text] [Related]
22. Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene.
Radi E; Formichi P; Di Maio G; Battisti C; Federico A
J Cell Mol Med; 2012 Aug; 16(8):1916-23. PubMed ID: 22117566
[TBL] [Abstract][Full Text] [Related]
23. Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations.
Behrens MI; Brüggemann N; Chana P; Venegas P; Kägi M; Parrao T; Orellana P; Garrido C; Rojas CV; Hauke J; Hahnen E; González R; Seleme N; Fernández V; Schmidt A; Binkofski F; Kömpf D; Kubisch C; Hagenah J; Klein C; Ramirez A
Mov Disord; 2010 Sep; 25(12):1929-37. PubMed ID: 20683840
[TBL] [Abstract][Full Text] [Related]
24. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability.
Santoro L; Breedveld GJ; Manganelli F; Iodice R; Pisciotta C; Nolano M; Punzo F; Quarantelli M; Pappatà S; Di Fonzo A; Oostra BA; Bonifati V
Neurogenetics; 2011 Feb; 12(1):33-9. PubMed ID: 20853184
[TBL] [Abstract][Full Text] [Related]
25. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
Park JS; Blair NF; Sue CM
Mov Disord; 2015 May; 30(6):770-9. PubMed ID: 25900096
[TBL] [Abstract][Full Text] [Related]
26. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death.
Ugolino J; Fang S; Kubisch C; Monteiro MJ
Hum Mol Genet; 2011 Sep; 20(18):3565-77. PubMed ID: 21665991
[TBL] [Abstract][Full Text] [Related]
27. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.
Ramirez A; Heimbach A; Gründemann J; Stiller B; Hampshire D; Cid LP; Goebel I; Mubaidin AF; Wriekat AL; Roeper J; Al-Din A; Hillmer AM; Karsak M; Liss B; Woods CG; Behrens MI; Kubisch C
Nat Genet; 2006 Oct; 38(10):1184-91. PubMed ID: 16964263
[TBL] [Abstract][Full Text] [Related]
28. Intermediate phenotype of ATP13A2 mutation in two Chilean siblings: Towards a continuum between parkinsonism and hereditary spastic paraplegia.
Miranda M; Harmuth F; Bustamante ML; Rossi M; Sturm M; Magnusson ÓT; Bauer P; Klockgether T; Ramirez A
Parkinsonism Relat Disord; 2020 Dec; 81():45-47. PubMed ID: 33049588
[No Abstract] [Full Text] [Related]
29. ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function.
Demirsoy S; Martin S; Motamedi S; van Veen S; Holemans T; Van den Haute C; Jordanova A; Baekelandt V; Vangheluwe P; Agostinis P
Hum Mol Genet; 2017 May; 26(9):1656-1669. PubMed ID: 28334751
[TBL] [Abstract][Full Text] [Related]
30. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.
Bras J; Verloes A; Schneider SA; Mole SE; Guerreiro RJ
Hum Mol Genet; 2012 Jun; 21(12):2646-50. PubMed ID: 22388936
[TBL] [Abstract][Full Text] [Related]
31. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
[TBL] [Abstract][Full Text] [Related]
32. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation.
Schneider SA; Paisan-Ruiz C; Quinn NP; Lees AJ; Houlden H; Hardy J; Bhatia KP
Mov Disord; 2010 Jun; 25(8):979-84. PubMed ID: 20310007
[TBL] [Abstract][Full Text] [Related]
33. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis.
Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F
Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336
[TBL] [Abstract][Full Text] [Related]
34. Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation.
Fong CY; Rolfs A; Schwarzbraun T; Klein C; O'Callaghan FJ
Eur J Paediatr Neurol; 2011 May; 15(3):271-5. PubMed ID: 21316993
[TBL] [Abstract][Full Text] [Related]
35. Novel mutations in ATP13A2 associated with mixed neurological presentations and iron toxicity due to nonsense-mediated decay.
Kırımtay K; Temizci B; Gültekin M; Yapıcı Z; Karabay A
Brain Res; 2021 Jan; 1750():147167. PubMed ID: 33091395
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.
Yang X; Xu Y
Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640
[TBL] [Abstract][Full Text] [Related]
37. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.
Paisán-Ruiz C; Guevara R; Federoff M; Hanagasi H; Sina F; Elahi E; Schneider SA; Schwingenschuh P; Bajaj N; Emre M; Singleton AB; Hardy J; Bhatia KP; Brandner S; Lees AJ; Houlden H
Mov Disord; 2010 Sep; 25(12):1791-800. PubMed ID: 20669327
[TBL] [Abstract][Full Text] [Related]
38. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.
Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D
J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086
[TBL] [Abstract][Full Text] [Related]
39. ATP13A2-related juvenile-onset Parkinson disease.
Suleiman J; El-Hattab AW
Brain Dev; 2019 Feb; 41(2):223. PubMed ID: 30144971
[No Abstract] [Full Text] [Related]
40. Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models.
Park JS; Koentjoro B; Davis RL; Sue CM
Parkinsonism Relat Disord; 2016 Jun; 27():67-73. PubMed ID: 27039055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
